Email this article Serotype-independent protective activity of recombinant pneumolysin in a model of systemic infection caused by Streptococcus pneumoniae serotypes 4 and 6B
- Authors: Vorobyev D.S.1,2, Petukhova E.S.1, Volokh Y.V.1, Afanasyeva O.М.1, Tokarskaya M.M.1, Leonova A.Y.1, Zhigunova O.V.1, Semenova I.B.1, Gavrilova N.F.1, Yakovleva I.V.1, Yastrebova N.E.1
-
Affiliations:
- I.I. Mechnikov Research Institute of Vaccines and Sera
- I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
- Issue: Vol 21, No 4 (2022)
- Pages: 71-75
- Section: ORIGINAL REPORTS
- Published: 10.12.2022
- URL: https://bioterapevt.abvpress.ru/jour/article/view/1359
- DOI: https://doi.org/10.17650/1726-9784-2022-21-4-71-75
- ID: 1359
Cite item
Full Text
Abstract
Background. The development of a pneumococcal vaccine with serotype-independent activity is relevant for the whole world, as this is due to the high prevalence of Streptococcus pneumoniae (S. pneumoniae), the constant change of pathogen serotypes and the growth of antibiotic-resistant strains. In previous experiments, we revealed a protective effect of immunization with recombinant pneumolysin (rPly) in a model of systemic infection caused by S. pneumoniae serotype 3.
Aim. Study of serotype-independent protective activity of rPly.
Materials and methods. Strains of S. pneumoniae serotypes 4 and 6B were used. Mice were immunized intraperi-toneally two or three times with an interval of 14 days with rPly. To assess the protective activity of rPly, animals after double or triple immunization were infected intraperitoneally with S. pneumoniae .
Results. rPly at a triple immunization in a dose of 25 μg protected mice from intraperitoneal infection with S. pneu- moniae serotype 4, the efficiency index increased by 2 times compared with the control. with a double immunization, rPly protected mice from intraperitoneal infection with S. pneumoniae serotype 6B, efficiency index increased by 6.61 times compared with the control.
Conclusion. rPly protects animals from infection with different serotypes of S. pneumoniae, which allows us to consider it a promising drug for the development of pneumococcal vaccines with serotype-independent activity.
About the authors
D. S. Vorobyev
I.I. Mechnikov Research Institute of Vaccines and Sera; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Author for correspondence.
Email: vorobievdenis@yandex.ru
ORCID iD: 0000-0002-1926-8803
Denis Sergeevich Vorobyev
5A Maly Kazenny Ln., Moscow 105064
Bld. 2, 8 Trubetskaya St., 119991 Moscow
Russian FederationE. S. Petukhova
I.I. Mechnikov Research Institute of Vaccines and Sera
ORCID iD: 0000-0003-0796-5764
5A Maly Kazenny Ln., Moscow 105064
Russian FederationYu. V. Volokh
I.I. Mechnikov Research Institute of Vaccines and Sera
ORCID iD: 0000-0002-5161-4964
5A Maly Kazenny Ln., Moscow 105064
Russian FederationO. М. Afanasyeva
I.I. Mechnikov Research Institute of Vaccines and Sera
ORCID iD: 0000-0003-0875-4141
5A Maly Kazenny Ln., Moscow 105064
Russian FederationM. M. Tokarskaya
I.I. Mechnikov Research Institute of Vaccines and Sera
ORCID iD: 0000-0002-5175-5433
5A Maly Kazenny Ln., Moscow 105064
Russian FederationA. Yu. Leonova
I.I. Mechnikov Research Institute of Vaccines and Sera
ORCID iD: 0000-0002-2889-2405
5A Maly Kazenny Ln., Moscow 105064
Russian FederationO. V. Zhigunova
I.I. Mechnikov Research Institute of Vaccines and Sera
ORCID iD: 0000-0002-3958-6219
5A Maly Kazenny Ln., Moscow 105064
Russian FederationI. B. Semenova
I.I. Mechnikov Research Institute of Vaccines and Sera
ORCID iD: 0000-0002-6630-4838
5A Maly Kazenny Ln., Moscow 105064
Russian FederationN. F. Gavrilova
I.I. Mechnikov Research Institute of Vaccines and Sera
ORCID iD: 0000-0001-6704-0339
5A Maly Kazenny Ln., Moscow 105064
Russian FederationI. V. Yakovleva
I.I. Mechnikov Research Institute of Vaccines and Sera
ORCID iD: 0000-0001-5123-2651
5A Maly Kazenny Ln., Moscow 105064
Russian FederationN. E. Yastrebova
I.I. Mechnikov Research Institute of Vaccines and Sera
ORCID iD: 0000-0002-6911-1345
5A Maly Kazenny Ln., Moscow 105064
Russian FederationReferences
- Brooks L.R.K., Mias G.I. Streptococcus pneumoniae’s virulence and host immunity: aging, diagnostics, and prevention. Front Immunol 2018;9:1366. doi: 10.3389/fimmu.2018.01366
- Weiser J.N., Ferreira D.M., Paton J.C. Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol 2018;16(6):355–67. doi: 10.1038/s41579-018-0001-8
- Masomian M., Ahmad Z., Gew L.T., Poh C.L. Development of next generation Streptococcus pneumoniae vaccines conferring broad protection. Vaccines (Basel) 2020;8(1):132. doi: 10.3390/vaccines8010132
- Briles D.E., Paton J.C., Mukerji R. et al. Pneumococcal vaccines. Microbiol Spectr 2019;7(6). doi: 10.1128/microbiolspec.gpp3-0028-2018
- Nishimoto A.T., Rosch J.W., Tuomanen E.I. Pneumolysin: pathogenesis and therapeutic target. Front Microbiol 2020;11:1543. doi: 10.3389/fmicb.2020.01543
- Vorobyev D.S., Semenova I.B., Volokh Yu.V. et al. Properties of native protein-containing antigens of Streptococcus pneumoniae. Mikrobiologiya = Microbiology 2019;1:22–8. (In Russ.). doi: 10.36233/0372-9311-2019-1-22-28
- Petukhova E.S., Vorobyev D.S., Sidorov A.V. et al. Immunization with recombinant pneumolysin induces the production of anti-bodies and protects mice in a model of systemic infection caused by Streptococcus pneumoniae. Bulleten eksperimentalnoy biologii i meditsiny = Bulletin of Experimental Biology and Medicine 2019;168(10):471–3. (In Russ.).
- Ashmarin I.P., Vorobyev A.A. Statistical methods in microbiological research. Leningrad: Medgiz, 1962. 183 p. (In Russ.)
Supplementary files
